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Abstract 
Goals: To determine whether patients with a pre‑existing PPI treatment had a higher risk of poor evolution (recur‑
rence or death) when diagnosed with a toxicogenic Clostridium difficile digestive infection.
Background: Previous studies identified pump proton inhibitor (PPI) prescription as a risk factor for C. difficile infec‑
tion. The influence of PPI on the outcome of C. difficile infection is controversial.
Study: This was a retrospective monocentric cohort study. All cases of patients in our center with a symptomatic 
infection by a toxicogenic C. difficile strain during the years 2012 and 2013 were retrospectively analyzed. The primary 
endpoint was the occurrence of a recurrence or C. difficile infection ‑related death within 2 months after diagnosis.
Results: 373 patients were included in this study (198 men and 175 women), with a mean age of 70.1 ± 18.6 years 
(2–100 years). Fourteen (3.7 %) patients died secondarily to C. difficile infection (median survival time 5 days), and 88 
(23.6 %) experienced recurrence (after a median delay of 30 days). One hundred and ninety eight (53.1 %) patients 
were already receiving PPI at the time of the C. difficile infection (including 156 patients with a prescription >1 month). 
When analyzing separately men and women, male patients were more likely to experience recurrence or death in 
case of pre‑existing PPI prescription [HR = 2.32 (1.26–4.27)]; this was not observed in female patients [HR = 0.62 
(0.31–1.22)].
Conclusions: Pre‑existing PPI therapy may increase the risk of recurrence or death in male patients with a toxico‑
genic C. difficile infection. PPI risk–benefit ratio should be carefully assessed.
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Background
Clostridium difficile infection (CDI) has become a com-
mon cause of acute diarrhea in adults. Over the last 
years, CDI incidence has increased three to eight times in 
the USA (Lessa et al. 2015; Gilca et al. 2010), along with 
the risk of complications (Pepin et  al. 2004); in Europe, 
the rise of an hypervirulent C. difficile strain (027 or 
NAP1) has been observed, this strain being responsi-
ble for more severe clinical forms and more recurrences 
(Davies et  al. 2014; Loo et  al. 2005). CDI has various 
clinical forms, from relatively benign afebrile or febrile 
diarrhea, to simple colitis, pseudomembranous colitis, 
severe sepsis, toxic megacolon, and  organ perforation; 
mortality rate of severe form reaches 50  % (Venugopal 
et al. 2013). Classical risk factors of CDI are recent hospi-
talization, antibiotic prescription, age over 65 years, and 
immunosuppression (Pacheco and Johnson 2013). In the 
last years, it has been suspected that proton pump inhibi-
tor (PPI) therapy may be a risk factor for CDI (Kwok 
et al. 2012; Janarthanan et al. 2012). PPI are widely pre-
scribed; in the USA, more than 11 million patients are 
treated with PPI (as a long term treatment) (Fashner and 
Gitu 2013), and overuse has been documented in Europe 
(Ramirez et al. 2010).
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The purpose of this study was to determine whether 
patients with a pre-existing PPI treatment had a higher 
risk of CDI recurrence or CDI-related death when diag-
nosed with a toxicogenic C. difficile strain.
Results
Population
From January 2012 to December 2013, Clostridium diffi-
cile was detected in feces of 592 patients. Three hundred 
and seventy-three patients meeting the inclusion crite-
ria (clinical symptoms including at least diarrhea, and 
fecal samples positive for toxicogenic C. difficile) were 
included. One hundred and ninety eight (53.1 %) patients 
were men and 175 (46.9 %) were women. The mean age 
was 70.1 ± 51.5–88.7 (2–100 years). Among the included 
patients, 5 were carrying the 027 C. difficile strain.
Among the 373 included patients, 198 (53.1  %) were 
receiving PPI before CDI; PPI therapy was initiated more 
than 1 month before CDI in 156 patients (41.8 %). Two 
hundred and seventy (72.4 %) patients received antibiot-
ics within a month before the infection, 269 (72.1 %) had 
been hospitalized in the 3 months prior to the CDI, and 
72 (19.3 %) were receiving long term immunosuppressive 
therapy (steroids, TNF-α blockers, anti-rejection therapy, 
cyclophosphamide, rituximab or azathioprine).
Concerning the CDI, 177 patients (47.4 %) had an afe-
brile diarrhea, 84 patients (22.5 %) had a febrile diarrhea, 
70 (18.8  %) a colitis, and 42 (11.3  %) a severe colitis. A 
total of 16 % of patients were lost to follow-up. Fifty-three 
patients died in the year following the diagnosis of CDI, 
including 14 patients whose death was directly due to 
CDI, with a median survival time of 5 days (1–56 days). 
Recurrence of CDI occurred in 88 patients (23.6 %), with 
a median delay of 30 days (7–173 days). As most (80 %) 
of relapse occurred in the 2 months following CDI diag-
nosis in a recent study (McDonald et al. 2015), we chose 
to consider this period in our study. When considering 
only the 2  months following the initial CDI diagnosis, 
recurrence of CDI occurred in 74 patients (19.8 %), with 
a median delay of 27 days (7–55 days). The relative fre-
quencies of CDI forms were not different in patients with 
and without pre-existing PPI therapy.
We then considered the composite risk of CDI recur-
rence or CDI-related death in the 2 months following the 
initial CDI diagnosis. In univariate analysis, this risk was 
higher in patients without immunosuppressive therapy 
(p =  0.02). Sex, age group (under/above 50  years), CDI 
clinical form and antibiotic therapy in the past month 
and hospital admission in the past 3  months were not 
associated with a distinctive evolution. Pre-existing PPI 
prescription during more than 1 month before CDI was 
not associated with a higher risk (p =  0.15); this differ-
ence was neither significant when considering all PPI 
prescription (p  =  0.27). When considering separately 
males and females, this composite risk of recurrence or 
C. difficile-related death was significantly associated with 
pre-existing PPI prescription more than 1  month prior 
CDI in males (p  <  0.01) but not in females (p  =  0.24) 
(Fig.  1). This composite risk was also significantly asso-
ciated with PPI prescription whatever the duration in 
males (p  =  0.04) but not in females (p  =  0.58). When 
considering the whole follow-up period, and not only 
2  months, the difference in the composite risk was still 
significantly associated with PPI in men (p  <  0.01) but 
not in women (p = 0.46); however, only few new events 
occurred after the first 2 months.
It is noteworthy that the rate of CDI-related death 
was too low to assess the association between this out-
come alone and PPI prescription. When considering CDI 
relapse alone, the risk was still significantly associated 
with PPI in men (p < 0.01) but not in women (nonsignifi-
cant trend of lower risk of relapse, p = 0.16).
In multivariate Cox model including sex, PPI prescrip-
tion >1 month, age group, previous hospitalization, pre-
vious antibiotic therapy, immunosuppressive therapy, 
and clinical form, PPI prescription was independently 
associated with a higher risk of recurrence of C. difficile 
related death in males [HR = 2.32 (1.26–4.27)] but not in 
females [HR = 0.62 (0.31–1.22)] (Table 1).
Discussion
Proton pump inhibitors are widely prescribed; however, 
their benefits may not deserve such common use (Katz 
2010). They may be frequently useless, and may be asso-
ciated with poorly appraised adverse effects, including 
osteoporosis (Gray et  al. 2010) and infections. Indeed, 
prospective and retrospective studies suggested that PPI 
may increase the risk of both community-acquired pneu-
monia and intensive care unit-acquired pneumonia (Eom 
et al. 2011), although this was not always observed (Fil-
ion et al. 2014). A meta-analysis also suggested that PPI 
prescription enhances the risk of spontaneous bacterial 
peritonitis in patients with ascites (Trikudanathan et  al. 
2011). Clostridium difficile infections may also be more 
frequent in patients receiving PPI; a large prospective 
study (Loo et  al. 2011) observed that PPI prescription 
was associated with a relative risk of CDI and coloniza-
tion of respectively 2.64 and 1.71; and a study of criti-
cally ill patients (Buendgens et al. 2014) showed that PPI 
prescription was associated with a relative risk of 3.11 of 
developing CDI in the intensive care unit. Meanwhile, 
two meta-analyses (Tleyjeh et al. 2012; Kwok et al. 2012) 
and a case–control study (Leonard et  al. 2012) do not 
support this association.
Some previous studies already explored the associa-
tion between PPI prescription and CDI outcome. In a 
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monocentric USA study (Freedberg et  al. 2013), PPI 
were associated with higher 90-day mortality in patients 
with CDI, but not with recurrence. Other studies 
observed that PPI prescription was associated with CDI 
recurrence in a USA population (hazard ratio 1.4) (Linsky 
et al. 2010), in a Canadian population (hazard ratio 1.5) 
(McDonald et al. 2015), and in a Korean population (Kim 
et al. 2012).
Our study also suggests that PPI prescription enhances 
the risk of CDI recurrence, but only in males. Gender 
has been associated with different CDI prognosis: in two 
USA studies, CDI were slightly more frequent in females 
(Lessa et  al. 2015), and C. difficile-associated death was 
nearly twice higher in female (Smith et al. 2015), but no 
difference was observed in another USA study (Boone 
et al. 2012). Conversely, a French study observed a higher 
frequency of severe forms in males (Khanafer et al. 2013). 
Our results also suggest that there is an independent link 
between male gender and outcome.
The mechanisms leading to more frequent and/or more 
recurrent CDI are only suspected. Stomach low pH prob-
ably acts as a chemical defense against ingested microor-
ganism, and drugs interfering with proton secretion are 
likely to limit this protection. Interestingly, a recent study 
(Freedberg et  al. 2015) observed that during PPI use, 
patient gut microbiome was modified, with a higher pro-
portion of bacterial taxa associated with CDI, suggesting 
that PPI may not only act on the ingested pathogens, but 
also on the normal gut flora.
Our study has several limitations, being monocen-
tric and retrospective. However, as all the patients were 
diagnosed in a single center, it ensured that CDI diag-
nosis was homogenous among the whole population. To 
prevent some of the bias induced by the retrospective 
collection of data, we chose to only consider the events 
occurring within 2  months after the CDI diagnosis, as 
more delayed events may be missed in a retrospective 
study. It should also be noted that the infectious disease 
team of our institution is routinely advised in case of 
Fig. 1 Kaplan–Meier curves of the composite risk of C. difficile infection (CDI) recurrence and CDI‑related death in males (a) and females (b), in 
patients with proton pump inhibitor prescription during more than 1 month before CDI diagnosis (bold line) and other patients (thin line)
Table 1 Relative risk of  CDI recurrence or CDI-related 
death: multivariate analysis
a Pre‑existing PPI therapy more than 1 month before






 Yes 0.62 0.33–1.22
PPI prescriptiona—men
 No 1.00
 Yes 2.32 1.26–4.27
Sex
 Female 1.00
 Male 0.51 0.28–0.94
Age
 <50 years 1.00
 >50 years 1.53 0.68–3.44
Previous hospitalization
 No 1.00
 Yes 1.71 0.98–2.97
Previous antibiotic therapy
 No 1.00
 Yes 0.95 0.59–1.52
Immunosupressive therapy
 No 1.00
 Yes 0.32 0.15–0.68
Clinical form
 Diarrhea 1.00
 Colitis 1.10 0.68–1.78
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toxigenic C. difficile detection in the other medical unit 
of the hospital, meaning that it is unlikely that diagnosed 
CDI recurrence have been missed.
Conclusion
Our study suggests that PPI use is associated with a 
higher risk of CDI recurrence and CDI-associated death 
in males. PPI prescription must be carefully appraised 
due to such adverse effects. Moreover, PPI should be 




The study was based on a retrospective cohort of patients 
diagnosed with a symptomatic infection by a toxicogenic 
C. difficile.
Ethical consideration
This study was specifically approved by the regional ethi-
cal authority (Comité de Protection des Personnes Sud-
Est V).
Patient inclusion
We retrospectively included patients with diarrhea and 
fecal isolation of a toxicogenic Clostridium difficile in 
Grenoble University Hospital between 1st January 2012 
and 31 December 2013. Patients without digestive symp-
toms or with a non-toxicogenic C. difficile strain were 
not included. Children aged less than 24  months were 
excluded, as the high rate of asymptomatic colonization 
in infants may interfere with diagnosis accuracy.
C. difficile infection diagnosis
Liquid stool samples were submitted for detection of tox-
igenic C. difficile by a two-step algorithm. The C. difficile 
algorithm began with the C. DIFF QUICK CHEK® test 
(TechLab), a membrane-bound enzyme immunoassays 
(EIA) that detects the glutamate dehydrogenase (GDH) 
antigen of C. difficile. From January to Mars 2012, a 
positive GDH result triggered the second-step TOX A/B 
QUICK CHEK® (TechLab) EIA for toxins A and B detec-
tion. For specimens with negative EIA results (GDH pos-
itive, Toxins A/B negative), a culture was performed and 
the TOX A/B QUICK CHEK® test was renewed from 
colonies. Subsequently, from April 2012, the second step 
of algorithm consisted of a direct stool PCR to detect the 
tcdB gene (Xpert® C. difficile, Cepheid).
Data collection
Patient characteristics were retrospectively collected 
in medical files: age, sex, immunosuppressive therapy, 
hospitalization within 3 months prior to CDI diagnosis, 
antibiotic treatment within 1  month prior to CDI diag-
nosis, and PPI therapy prior to CDI diagnosis as well 
as whether this treatment was established more than 
1  month before CDI. C. difficile antibiotic therapy was 
also collected and four clinical forms were considered: 
afebrile diarrhea, febrile diarrhea, colitis, and severe 
colitis. Complications, CDI recurrence, and/or C. diffi-
cile-related death were collected during the 2-months 
following CDI diagnosis.
The primary endpoint was the occurrence of a CDI 
recurrence or a CDI-related death within 2-months after 
diagnosis.
Data analysis
Survival and recurrence-free survival were analyzed by 
the Kaplan–Meier method and Log-rank tests. The effect 
of PPI on the primary endpoint was adjusted for con-
founding factors using a Cox proportional hazard model. 
Potential confounding factors included were as follows: 
sex, age group (<50; ≥50 years), previous hospitalization, 
previous antibiotic therapy, immunosuppressive therapy, 
and clinical form. We tested for significance an interac-
tion term between sex and PPI to assess if the effect of 
PPI was different in men and women.
Two-sided p values less than 0.05 were considered sta-
tistically significant. Analyses were performed using Stata 
version 13.0 (Stata Corporation, College Station, TX, 
USA).
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CDI: Clostridium difficile infection; PPI: Proton pump inhibitor.
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